Benjamin Martin, MD
Family Medicine · Wayne, NENPI 1669427613
Payments from drug & device makers
Across 64 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$245
- AstraZeneca$155
- AbbVie$123
- Astellas Pharma US Inc$102
- Merck$86
- Pfizer$50
- plus $306 from 13 others
What the payments were for
- Food & beverage$1,068100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $245 |
| AstraZeneca | 3 | $155 |
| AbbVie(2 entities) | 7 | $123 |
| Astellas Pharma US Inc | 6 | $102 |
| Merck | 6 | $86 |
| Pfizer | 4 | $50 |
| Boehringer Ingelheim | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| Lilly USA, LLC | 3 | $37 |
| Novo Nordisk | 2 | $36 |
| Grifols USA, LLC | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Novartis | 1 | $17 |
| Abbott | 1 | $17 |
| Bayer | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Organon | 2 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$119
How this compares
$1,068 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 193 | $110,538 |
| JardianceEmpagliflozin | 52 | $37,608 |
| MounjaroTirzepatide | 24 | $22,978 |
| CaplytaLumateperone Tosylate | 14 | $21,611 |
| MyrbetriqMirabegron | 40 | $17,505 |
| OzempicSemaglutide | 17 | $14,935 |
| Repatha SureclickEvolocumab | 19 | $13,320 |
| JanuviaSitagliptin Phosphate | 15 | $13,263 |
| LinzessLinaclotide | 23 | $12,707 |
| TradjentaLinagliptin | 16 | $10,921 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $10,006 |
| KonvomepOmeprazole/Sodium Bicarbonate | 25 | $9,320 |
| FarxigaDapagliflozin Propanediol | 13 | $7,152 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $5,813 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $50 | $110,538193 claims |
| Boehringer IngelheimJardiance, Tradjenta | $47 | $48,53068 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $37 | $24,408105 claims |
| MerckJanuvia, Janumet Xr | $86 | $19,07626 claims |
| Astellas Pharma US IncMyrbetriq | $102 | $17,50540 claims |
| Novo NordiskOzempic | $36 | $14,93517 claims |
| AbbVieLinzess, Synthroid | $123 | $14,38847 claims |
| AstraZenecaFarxiga | $155 | $7,15213 claims |
| GSKBreo Ellipta | $15 | $4,80512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Wayne
- Alfred FelberWayne$287K
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.